Salivary antibodies induced by BA.4/BA.5-convalescence or bivalent booster Immunoglobulin vaccination protect against novel SARS-COV-2 variants of concern
ABSTRACT Currently, SARS-CoV-2 Omicron BA.5 subvariants BF.7 and BQ.1.1 are rapidly emerging worldwide. To evaluate the SARS-CoV-2-neutralizing capacity of sera and saliva from triple vaccinated individuals, either boosted with an adapted bivalent COVID-19 vaccine or recovered from BA.4/BA.5 infecti...
Main Authors: | Gabriel Diem, Stefanie Dichtl, Viktoria Zaderer, Cornelia Lass-Flörl, Markus Reindl, Gaia Lupoli, Christopher Dächert, Maximilian Muenchhoff, Alexander Graf, Helmut Blum, Oliver T. Keppler, Doris Wilflingseder, Wilfried Posch |
---|---|
Format: | Article |
Language: | English |
Published: |
American Society for Microbiology
2023-10-01
|
Series: | Microbiology Spectrum |
Subjects: | |
Online Access: | https://journals.asm.org/doi/10.1128/spectrum.01793-23 |
Similar Items
-
Vaccination and Omicron BA.1/BA.2 Convalescence Enhance Systemic but Not Mucosal Immunity against BA.4/5
by: Gabriel Diem, et al.
Published: (2023-06-01) -
ColdZyme® protects airway epithelia from infection with BA.4/5
by: Zaderer Viktoria, et al.
Published: (2022-10-01) -
Correction: ColdZyme® protects airway epithelia from infection with BA.4/5
by: Viktoria Zaderer, et al.
Published: (2023-01-01) -
Cilgavimab/Tixagevimab as alternative therapeutic approach for BA.2 infections
by: Stefanie Dichtl, et al.
Published: (2022-09-01) -
Omicron subvariants illustrate reduced respiratory tissue penetration, cell damage and inflammatory responses in human airway epithelia
by: Viktoria Zaderer, et al.
Published: (2023-10-01)